Answers are grounded in this paper and cite their sources.
A newly encountered designer drug “N1-cyclopropylmethanoyl-lysergicaciddiethylamide (1cP-LSD)” is an acylated derivative of LSD. Based on the structural characteristics, 1cP-LSD is expected to be readily metabolized to LSD, which can make it difficult to discriminate between intakes of 1cP-LSD and LSD. In this study, to obtain the fundamental information needed for proving intake of 1cP-LSD, the metabolism experiments were performed using human liver microsomes (HLM). 1cP-LSD and its 10 metabolites were detected in HLM reaction mixtures of 1cP-LSD using liquid chromatography-high resolution-tandem mass spectrometry with a C18 semi-micro column and the time-course changes in concentrations of them were observed during the first 120 minutes of the reactions. The results demonstrated that 1cP-LSD rapidly decreased in microsomal mixtures (half-life time: 5 min) and a metabolic reaction by carboxylesterase, expressed abundantly in liver, was mostly responsible for the decrease. This short half-life of 1cP-LSD implied biological samples such as urine and blood should be collected from suspects as soon as possible after intake for detecting unchanged 1cP-LSD, which can lead to the proof of intake. Four out of 10 microsomal metabolites (hydroxy-, N-desethyl-, N6-desmethyl and N-desethyl-N6-desmethyl metabolites) could also be useful indicators for proving intake of 1cP-LSD since they retain a cyclopropylmethanoyl group. Especially, the N6-desmethyl metabolite appeared to be a more appropriate indicator because it could be detected in microsomal mixtures over longer periods.
No takes yet. Share an insight, caveat, or question.
Miyake et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: